Spinal injection may shield brain from lymphoma spread
NCT ID NCT07493486
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a chemotherapy drug called thiotepa, given via spinal injection, to prevent lymphoma from spreading to the brain or spinal cord in people with high-risk diffuse large B-cell lymphoma (DLBCL). 31 participants received the treatment and were followed for 2 years to see how many developed central nervous system (CNS) relapse. The goal was to find a safer and effective way to protect the brain without harsh side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK-POSITIVE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo aims to tame aggressive lymphoma in frail patients
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- New drug combo aims to boost lymphoma treatment
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Engineered immune cells take aim at Tough-to-Treat blood cancers
- Brain fog after lymphoma: study probes lasting cognitive effects of chemotherapy